This file photo shows the exterior of the headquarters of Swiss biotechnology group Actelion in Allschwil, near Basel. U.S. pharmaceuticals giant Johnson & Johnson on Jan. 26 announced it was buying Swiss medical firm Actelion for $30-billion.